AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660
Kloeckner R, Galle PR, Bruix J. Local and regional therapies for hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):137–49. https://doi.org/10.1002/hep.31424
Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START‐FIT): a single‐arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:169–78. https://doi.org/10.1016/s2468-1253(22)00339-9
Sun HC, Zhou J, Wang Z, Liu X, Xie Q, Jia W, et al. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surg Nutr. 2022;11(2):227–52. https://doi.org/10.21037/hbsn-21-328
Zhang Y, Huang G, Wang Y, Liang L, Peng B, Fan W, et al. Is salvage liver resection necessary for initially unresectable hepatocellular carcinoma patients downstaged by transarterial chemoembolization? Ten years of experience. Oncol. 2016;21(12):1442–9. https://doi.org/10.1634/theoncologist.2016-0094
Li Z, Cheng H, Mao J, Liu G. Conversion therapy of intermediate and advanced hepatocellular carcinoma using superstable homogeneous iodinated formulation technology. Sci China Life Sci. 2022;65(10):2114–17. https://doi.org/10.1007/s11427-022-2142-3
He P, Ren E, Chen B, Chen H, Cheng H, Gao X, et al. A super‐stable homogeneous Lipiodol‐hydrophilic chemodrug formulation for treatment of hepatocellular carcinoma. Theranostics. 2022;12(4):1769–82. https://doi.org/10.7150/thno.68456
Peng Y, He P, Gao X, Liu G, Cheng H. A superstable homogeneous lipiodol‐nanoformulation to overcome the dilemma of interventional embolization chemotherapy. Front Bioeng Biotechnol. 2022;10:952194. https://doi.org/10.3389/fbioe.2022.952194
Ikeda M, Arai Y, Inaba Y, Tanaka T, Sugawara S, Kodama Y, et al. Conventional or drug‐eluting beads? Randomized controlled study of chemoembolization for hepatocellular carcinoma: JIVROSG‐1302. Liver Cancer. 2022;11(5):440–50. https://doi.org/10.1159/000525500
Hu Z, Fang C, Li B, Zhang Z, Cao C, Cai M, et al. First‐in‐human liver‐tumour surgery guided by multispectral fluorescence imaging in the visible and near‐infrared‐Ⅰ/Ⅱ windows. Nat Biomed Eng. 2020;4(3):259–71. https://doi.org/10.1038/s41551-019-0494-0
Goumard C, Komatsu S, Brustia R, Fartoux L, Soubrane O, Scatton O. Technical feasibility and safety of laparoscopic right hepatectomy for hepatocellular carcinoma following sequential TACE‐PVE: a comparative study. Surg Endosc. 2017;31(5):2340–9. https://doi.org/10.1007/s00464-016-5225-y
He P, Xiong Y, Luo B, Liu J, Zhang Y, Xiong Y, et al. An exploratory human study of superstable homogeneous lipiodol‐indocyanine green formulation for precise surgical navigation in liver cancer. Bioeng Transl Med. 2023;8(2):e10404. https://doi.org/10.1002/btm2.10404
He P, Xiong Y, Ye J, Chen B, Cheng H, Liu H, et al. A clinical trial of super‐stable homogeneous lipiodol‐nanoICG formulation‐guided precise fluorescent laparoscopic hepatocellular carcinoma resection. J Nanobiotechnol. 2022;20(1):250. https://doi.org/10.1186/s12951-022-01467-w
Morse MA, Sun W, Kim R, He AR, Abada PB, Mynderse M, et al. The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res. 2019;25(3):912–20. https://doi.org/10.1158/1078-0432.ccr-18-1254
Chen H, Cheng H, Dai Q, Cheng Y, Zhang Y, Li D, et al. A superstable homogeneous lipiodol‐ICG formulation for locoregional hepatocellular carcinoma treatment. J Contr Release. 2020;323:635–43. https://doi.org/10.1016/j.jconrel.2020.04.021
Zhang Y, Cheng H, Chen H, Xu P, Ren E, Jiang Y, et al. A pure nanoICG‐based homogeneous lipiodol formulation: toward precise surgical navigation of primary liver cancer after long‐term transcatheter arterial embolization. Eur J Nucl Med Mol Imag. 2022;49(8):2605–17. https://doi.org/10.1007/s00259-021-05654-z
Xiong Y, He P, Zhang Y, Chen H, Peng Y, He P, et al. Superstable homogeneous lipiodol‐ICG formulation: initial feasibility and first‐in‐human clinical application for ruptured hepatocellular carcinoma. Regen Biomater. 2023;10:rbac106. https://doi.org/10.1093/rb/rbac106
Datta J, Narayan RR, Kemeny NE, D'Angelica MI. Role of hepatic artery infusion chemotherapy in treatment of initially unresectable colorectal liver metastases: a review. JAMA Surg. 2019;154(8):768–76. https://doi.org/10.1001/jamasurg.2019.1694
Yu J, Gao B. Molecular imaging for cancer immunotherapy. iRadiology. 2023;1(1):3–17. https://doi.org/10.1002/ird3.12
Chen H, Teng M, Zhang H, Liang X, Cheng H, Liu G. Advanced radionuclides in diagnosis and therapy for hepatocellular carcinoma. Chin Chem Lett. 2022;33(7):3371–83. https://doi.org/10.1016/j.cclet.2022.03.079
He P, Guan S, Ren E, Chen H, Chen H, Peng Y, et al. Precision interventional brachytherapy: a promising strategy toward treatment of malignant tumors. Front Oncol. 2021;11:753286. https://doi.org/10.3389/fonc.2021.753286
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
